The world has witnessed an incredible evolution in healthcare thanks to cord blood and tissue banking. This industry, which kick-started in the 1990s, has grown into a global powerhouse, controlling the fate of potentially life-saving treatments for countless diseases. The journey began in October 1988 with a groundbreaking procedure using cord blood-derived stem cells. Fast…

The global stem cell banking market is expected to grow from $8 billion in 2022 to $14.3 billion by 2030. This essentially means that more and more people and institutions are investing in storing stem cells for future use. What are stem cells, and why are they important? Stem cells are the body’s raw materials…

Cryo-Cell International, a leader in cord blood banking, has announced its financial results for the second quarter of 2023. For those unfamiliar, cord blood banking involves collecting and storing the blood from a newborn’s umbilical cord, which contains valuable stem cells that can be used in medical treatments. What You Need to Know: A Quick…

According to a recent report, the U.S. cord blood banking services market is expected to reach a value of USD 16.59 billion by 2030, with a compound annual growth rate (CAGR) of 11.56%. Cord blood, which contains hematopoietic stem cells, has shown promising results in the treatment of certain diseases in children, such as hematologic…

Biobanking is a rapidly growing industry that is expected to revolutionize healthcare. With increasing investments in regenerative medicine and personalized medicine, biobanks are becoming crucial for drug discovery and understanding the genetic basis of human diseases. The demand for medical data sets in biobanks has led to the rise of precision medicine, which aims to…

Presentation: Viera BioScience will present at the 2017 Academy of Regenerative Practices Conference on February 25th. The talk will cover preclinical and clinical data of AngioMune, a cord blood derived product. Product: AngioMune is a “universal donor” T regulatory cell product that can stimulate angiogenesis, or new blood vessel formation. It has potential applications for…

Patent Award: Targazyme Inc., a biopharmaceutical company, has been awarded a US patent for fucosylation of various therapeutic cells to improve their targeting and homing to sites of tumors and inflammation. Fucosylation Technology: Fucosylation is an enzyme-based platform technology that treats therapeutic cells at the point-of-care before infusion into the patient. It aims to improve…